Eloxx Pharmaceuticals, Inc. filed its 10-K on Mar 31, 2023 for the period ending Dec 31, 2022. In this report its auditor, Baker Tilly, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9 USD | -1.76% | +5.26% | -25.00% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.00% | 3.02M | |
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |
- Stock Market
- Equities
- ELOX Stock
- News Eloxx Pharmaceuticals, Inc.
- Eloxx Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt